Two female scientists dedicated to developing new advancements in medicine.
A group of young adults practicing yoga outside, feeling confident, connected and healthy.
A male and female scientist examine a test tube to asses a breakthrough that could transform current treatment paradigms.
A middle-aged woman and her young daughter happily spending time together outside.
Two female scientists dedicated to creating a breakthrough treatment that could change the lives of patients.
A young father laughs with joy as he plays with his ballerina daughter and lifts her high into the air.
A three-dimensional rendering of a monoclonal antibody (mAb).

Our pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP), and is currently in late-stage clinical development for the prevention of migraine.


A tablet on a stack of newspapers displaying the Alder BioPharmaceuticals website.

Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results

Data presented at American Academy of Neurology and American Headache Society Annual Meetings continue to support eptinezumab’s differentiated clinical profile and impact on... LEARN MORE

The U.S. Food and Drug Administration (FDA) accepted Alder’s Biologics License Application for eptinezumab in April 2019, with a Prescription Drug User Fee Act (PDUFA) target action date of February 21, 2020.

CONTACT US General inquiries:
Click here

ADDRESS & PHONE / FAX Corporate Headquarters
Alder BioPharmaceuticals, Inc.
11804 North Creek Parkway South
Bothell, WA 98011

Phone: 425-205-2900
Fax: 425-205-2901